Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Thalamic nuclei insights into Alzheimer's disease.

bioRxiv : the preprint server for biology·2026
Same author

Continuous Apomorphine Infusion in Multiple System Atrophy Real-World Insights From a French Nationwide Retrospective Cohort.

Movement disorders clinical practice·2026
Same author

Altered cerebrovascular haemodynamics in Parkinson's disease: Insights from 4D flow MRI.

NPJ Parkinson's disease·2026
Same author

The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Jun 9, 2025

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.4K

The New Zealand Parkinson's progression programme.

Michael R MacAskill1,2, Toni L Pitcher1,2, Tracy R Melzer1,2,3

  • 1New Zealand Brain Research Institute, Christchurch, New Zealand.

Journal of the Royal Society of New Zealand
|October 23, 2024
PubMed
Summary
This summary is machine-generated.

The New Zealand Parkinson's Progression Programme (NZP3) has studied cognitive impairment in Parkinson's disease for 14 years. It identified biomarkers and established criteria for mild cognitive impairment (MCI) in Parkinson's patients.

Keywords:
Parkinson’s diseasecognitive impairmentdementialongitudinal assessmentneuropsychology

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.4K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

25.6K

Related Experiment Videos

Last Updated: Jun 9, 2025

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.4K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.4K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

25.6K

Area of Science:

  • Neurology
  • Neuroscience
  • Biomarker Research

Background:

  • The New Zealand Parkinson's Progression Programme (NZP3) has been running for 14 years.
  • It involves 354 individuals with Parkinson's disease and 89 healthy controls.
  • Research focuses on cognitive impairment and its early detection in Parkinson's disease.

Purpose of the Study:

  • To characterize cognitive impairment in Parkinson's disease.
  • To identify biomarkers for predicting future cognitive decline.
  • To establish standardized criteria for mild cognitive impairment (MCI) in Parkinson's.

Main Methods:

  • Longitudinal study design over 14 years.
  • Participant recruitment of individuals with Parkinson's disease and healthy controls.
  • Utilizing brain imaging (MRI, PET), genetic analysis, fluid biomarkers, eye movement, speech analysis, and quantitative electroencephalography (EEG).

Main Results:

  • Significant contributions to understanding mild cognitive impairment (MCI) in Parkinson's disease.
  • Development and validation of standardized criteria for MCI.
  • Established associations between brain pathology (via MRI/PET) and cognitive decline.

Conclusions:

  • The NZP3 programme has advanced the understanding and diagnosis of cognitive impairment in Parkinson's disease.
  • It serves as a platform for diverse research, including epidemiology and caregiver burden.
  • The programme has fostered a skilled research community and produced numerous publications and theses.